SCHEMBL2359528

SCHEMBL2359528

Cc1c(C(=O)Nc2ccc(S(C)(=O)=O)c(Cl)c2)cc(C[C@H](C)O)n1-c1ccc(F)cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 5/20 0.63
NPY2R P49146 2/20 0.37
NPY1R P25929 1/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
AVPR2 P30518 1/20 0.37
OXTR P30559 1/20 0.37
AVPR1A P37288 1/20 0.37
GRM4 Q14833 5/20 0.36
GRM1 Q13255 4/20 0.36
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ENPP2 Q13822 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2358002 0.94 NR3C2 (0.62) NR3C2NPY2RNPY1RNPC1RAB9A
SCHEMBL2358996 0.94 NR3C2 (0.62) NR3C2SMN1; SMN2AVPR2OXTRAVPR1A
SCHEMBL2359339 0.94 NR3C2 (0.62) NR3C2NPY2RNPY1RNPC1RAB9A
SCHEMBL2360202 0.92 NR3C2 (0.58) NR3C2NPY2RNPY1RNPC1RAB9A
SCHEMBL2550462 0.91 NR3C2 (0.69) NR3C2NPY2RNPY1RSMN1; SMN2LMNA
SCHEMBL2544782 0.90 NR3C2 (0.64) NR3C2NPY2RNPY1RNPC1RAB9A
SCHEMBL2359373 0.90 NR3C2 (0.77) NR3C2RAB9ASMN1; SMN2AVPR2LMNA
SCHEMBL2357327 0.86 NR3C2 (0.60) NR3C2RAB9ASMN1; SMN2GRM4HTT
SCHEMBL2358468 0.84 NR3C2 (0.64) NR3C2NPY2RNPY1R
SCHEMBL2359896 0.83 NR3C2 (0.57) NR3C2SMN1; SMN2ENPP2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642640-B2 1-phenylpyrrole derivatives EXELIXIS, INC. (US) 2014-02-04 US disclosed
US-8642640-B2 1-phenylpyrrole derivatives EXELIXIS, INC. (US) 2014-02-04 US disclosed
US-8642640-B2 1-phenylpyrrole derivatives EXELIXIS, INC. (US) 2014-02-04 US disclosed
EP-2349996-B1 1-PHENYLPYRROLE COMPOUNDS EXELIXIS INC (US) 2014-01-01 EP disclosed
US-20110263544-A1 1-Phenylpyrrole Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-10-27 US disclosed
US-20110263544-A1 1-Phenylpyrrole Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-10-27 US disclosed
US-20110263544-A1 1-Phenylpyrrole Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-10-27 US disclosed
EP-2349996-A1 1-PHENYLPYRROLE COMPOUNDS Exelixis, Inc. (US) 2011-08-03 EP disclosed
WO-2010042626-A1 1-PHENYLPYRROLE COMPOUNDS EXELIXIS, INC. (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263544-A1 1-Phenylpyrrole Derivatives REN, AGTR1, NR3C2 NR3C2 3/4885NPY2R 1193/4885NPY1R 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.